Document:

Document

Exhibit 10.66

9 November 2021 Mr. Neil Josephson
Interim Chief Medical Officer

Promotion to Chief Medical Officer

Dear Neil,

On behalf of the Board of Directors of Zymeworks Inc. (“Zymeworks”), I am pleased to confirm your promotion to the position of Chief Medical Officer, effective 15 November 2021, and the following changes to your compensation:

									
		Current	New

	Base Salary (USD)	$453,200	$480,000
	Bonus Target	35% + 5% Interim	40%

The increase in base salary will be reflected starting on your 30 November 2021 pay.

Subject to approval of the Board or an authorized committee thereof: (i) you will also receive equity awards worth a total of $2,000,000 USD, to be issued in a 75% stock option and 25% restricted stock unit (RSU) mix on or as soon as practicable after 10 November 2021; and (ii) if prior to the first anniversary of the grant date Zymeworks (A) removes you from the role of Chief Medical Officer or (B) terminates your employment without cause (the effectiveness of such removal or termination, the “Acceleration Date”), the date upon which 25% of such stock options become exercisable and 25% of such RSUs become vested shall be accelerated to such Acceleration Date.

You will be notified via email when your stock option and RSU grants are ready for your review and acceptance in Shareworks.

Your revised compensation is based on a market assessment of Zymeworks’ compensation practices and your contributions to Zymeworks’ goals and ongoing efforts to make Zymeworks a world leader in antibody and protein therapeutics.

All other terms and conditions of your employment contract remain unchanged.

Neil, I want to personally thank you for all your contributions and commitment to Zymeworks’ success. This promotion is well-earned and well-deserved.

Sincerely,

/s/ Ali Tehrani

Dr. Ali Tehrani
President & Chief Executive Officer

Zymeworks Biopharmaceuticals Inc.  |  1215 4th Avenue, Suite 2100, Seattle WA, 98161| zymeworks.comDocument

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.

FIRST AMENDMENT TO
LICENSE AGREEMENT NO. A18025
 
This First Amendment to License Agreement No. A18025 effective December 13, 2021 (“First Amendment”), is entered into among The University of Florida Research Foundation, Inc., a not-for-profit corporation duly organized and existing under the laws of the State of Florida and having its principal office at 310 Walker Hall, Gainesville, Florida  32611 (“UFRF”), The Trustees of the University of Pennsylvania, a nonprofit corporation with offices located at Penn Center for Innovation, 3600 Civic Center, 9th floor, Philadelphia, PA  19104 (“Penn”, together with UFRF, the “Licensors”) and IVERIC Bio Gene Therapy LLC, a Delaware limited liability company having a place of business at Five Penn Plaza, Suite 2372, New York, NY 10001 (hereinafter referred to as “Licensee”).

WHEREAS, the parties entered into and are party to a license agreement effective June 6, 2018 (hereinafter “License Agreement”) Capitalized terms used but not defined herein shall have the meaning ascribed to them in the License Agreement; and;
 
WHEREAS, the parties now wish to amend the License Agreement by this First Amendment; 
 
NOW THEREFORE, in consideration of the premises and mutual covenants contained herein the parties hereto agree as follows:
 
1.       Section 3.2(a) of the License Agreement is hereby deleted and replaced with the following::
 

    (a)    Licensee agrees that the First Commercial Sale of Licensed Products to a customer shall occur on or before [**].  In addition, if Licensee fails to achieve such First Commercial Sale within such timeframe or to meet the milestones shown in Appendix E (as such dates or milestones may be extended in accordance with Section 3.2(b), Licensors may terminate this Agreement pursuant to Section 9.3.  Licensee shall notify Licensors in writing as each milestone is met. 

 2.           The Milestones detailed in Appendix E – Milestones of the License Agreement is hereby deleted  and replaced with the attached Amended Appendix E - Milestones.

3.    This First Amendment, together with the License Agreement, constitute the entire agreement between the parties. All other provisions of the License Agreement, except as expressly amended by this First Amendment,  shall remain in full force and effect and unmodified by this First Amendment.
 
4.       Licensors acknowledge  Licensee may file a copy of this First Amendment with the securities and exchange commission, in accordance with its rules and regulations.

5.    This First Amendment may be executed in two or more counterparts, each of which shall be deemed an original and together shall be deemed one and the same instrument.
 
UNIVERSITY OF FLORIDA                                    IVERIC Bio Gene Therapy LLC
RESEARCH FOUNDATION, INC.
 

By: _/s/ Jim O’Connell________________                By: __/s/ Keith Westby_____________
Name: Jim O'Connell                                           Name: Keith Westby
Title: Director, UF Innovate|Tech Licensing                Title: SVP, Chief Operating Officer
 
Date: _12/14/2021________________                        Date: _12/17/2021______________
 
THE TRUSTEES OF THE UNIVERSITY OF
PENNSYLVANIA

By: _/s/ Benjamin Dibling____________     
Name: Benjamin Dibling, Ph.D.
Title: Executive Director of Licensing, Penn Center for Innovation

Date:  12/13/2021____________________     

AMENDED APPENDIX E – MILESTONES

Event                                    Time

[**]                                [**]
[**]                                [**]        
[**]                                [**]Document

			
	

June 16, 2021
[**]

Dear Chris:
On behalf of IVERIC bio, Inc. (the “Company”) it is my pleasure to extend to you this offer of employment with the Company for the position of Senior Vice President & Chief Commercial Officer, reporting to Glenn Sblendorio, Chief Executive Officer.  The terms of this offer, which are contingent on you and us determining a mutually agreed upon start date (the “Start Date”) and satisfactory completion of a background investigation, are as follows:
1.Employment.  You will be employed on a full-time basis. You will carry out duties and responsibilities consistent with your position and other duties as may from time to time be assigned to you by the Company.  The Company reserves the right to change your title and responsibilities at any time, with or without notice.  You shall perform and discharge faithfully and diligently your duties and responsibilities hereunder.  You agree to devote your full business time, efforts, skill, knowledge, attention and energies to the advancement of the Company’s business and interests and to the performance of your duties and responsibilities as an employee of the Company.  You agree to abide by the rules, regulations, instructions, practices and policies of the Company and any changes to these that may be adopted from time to time by the Company.  

2.Base Salary.  Your base salary will be at the annual rate of $415,000, less all applicable taxes and withholdings, to be paid in accordance with the Company’s regular payroll practices.  Such base salary may be adjusted from time to time in accordance with normal business practices and in the sole discretion of the Company. Your position is classified as “exempt” according to federal wage law which means you are not eligible for overtime pay for hours worked in excess of 40 in a given week.

3.Discretionary Bonus.  Following the end of each calendar year and subject to the approval of the Company’s Board of Directors (the “Board”), you will be eligible for a  performance bonus of up to 45% of your annualized base salary, based on your personal performance and the Company’s performance during the applicable calendar year, as determined by the Company in its sole discretion.  To receive a bonus for the current performance year, you must be an active employee by September 30th and you must be an active employee of the Company on the date the bonus is distributed in 
    

order to be eligible for and to earn any bonus award.  Provided that you are an active employee of the Company on the date the bonus is distributed, we will guarantee your full bonus payout (based on your 45% target, but subject to the Company’s and your performance) for 2021 and you will be able to participate (on a pro rata basis based on your hire date) to the extent the Company achieves its stretch goals for up to an additional 50% of your target bonus.
4.Equity.  In connection with the commencement of your employment and as an inducement to becoming an employee, you will be eligible to receive an option to purchase 160,000 shares of the Company’s common stock (the “Option”), subject to approval by the Board (acting in its sole discretion) and contingent upon your execution of the corresponding stock option agreement.  The Option would be issued with an exercise price equal to the fair market value of the Company’s common stock (as determined by the Board) as of your Start Date (the “Grant Date”) and would vest over a four-year period, with 25% of the shares vesting on the first anniversary of the Grant Date and the remainder of the shares vesting in equal monthly amounts thereafter until the fourth anniversary of the Grant Date, pursuant to the terms of the stock option agreement and subject to your continued employment with the Company. In addition, in connection with the commencement of your employment and as an inducement to becoming an employee, you will be eligible to receive a restricted stock unit grant for 75,000 shares (the “Joining RSU Grant”) on the Grant Date, subject to approval by the Board (acting in its sole discretion) and contingent upon your execution of a corresponding restricted stock unit agreement.  The Joining RSU Grant would vest over a four-year period, with 25% of the shares vesting on each of the first, second, third and fourth anniversaries of the Grant Date, pursuant to the terms of the restricted stock unit agreement and subject to your continued employment with the Company.  Subject to Board approval each year, the Company grants additional equity awards annually based on performance.  You would be eligible for an annual performance-based equity award for 2021 on a pro-rata basis (pro-rated at 75%).

5.Sign On Bonus:  In connection with the commencement of your employment and as an inducement to becoming an employee, you will be eligible receive, as a sign-on bonus, a restricted stock unit grant for 15,000 shares of the Company’s common stock (the “Sign-On RSU Grant”) on the Grant Date, subject to approval by the Board (acting in its sole discretion) and contingent upon your execution of a corresponding restricted stock unit agreement.  The Sign-On RSU Grant would vest with respect to 100% of the shares underlying the grant on the first anniversary of the Grant Date, pursuant to the 
    

terms of the restricted stock unit agreement and subject to your continued employment with the Company.

6.Benefits.  You may participate in any and all benefit programs that the Company establishes and makes generally available to similarly situated employees from time to time, provided that you are eligible under (and subject to all provisions of) the plan documents that govern those programs.  A summary of current benefits is enclosed with this letter. Benefits are subject to change at any time in the Company’s sole discretion.
7.Severance.  You will be eligible to receive the severance and change in control benefits set forth in a separate written agreement with the Company to be executed contemporaneous herewith.

8.Car Allowance.  You will receive a semi-monthly car allowance in the amount of $675 less taxes ($1,350 per month).
9.Vacation.  You will be entitled to vacation time as set forth in the Employee Handbook, as such vacation policy may be amended by the Company from time to time.
10.Fair Competition & Confidentiality Agreement.   As a condition of employment, you will be required to execute the attached Fair Competition & Confidentiality Agreement. 
11.No Conflict.  You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this offer letter.
12.Proof of Legal Right to Work.  You will be required to complete an Employment Eligibility Verification Form and submit an original document or documents that establish identity and employment eligibility within 3 business days of starting employment.  Your employment with the Company is contingent on your satisfactory completion of this requirement.
13.At-Will Employment.  This letter shall not be construed as an agreement, either express or implied, to employ you for any stated term, and shall in no way alter the Company’s policy of employment at-will, under which both the Company and you 
    

remain free to end the employment relationship for any reason, at any time, with or without cause or notice.  Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at-will” nature of your employment may only be changed by a written agreement signed by you and the Company’s Chief Executive Officer that expressly states the intention to modify the at-will nature of your employment.  Similarly, nothing in this letter shall be construed as an agreement, either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company.  This letter supersedes all prior understandings, whether written or oral, relating to the terms of your employment.
14.Background Investigation.  The required notices and forms for our background investigation are enclosed herewith. You must submit a completed form with your signed offer letter.  Employment is contingent upon successful completion of the background check.

    

If you decide to accept this offer, and agree to the employment terms set forth in this letter, please sign the letter in the space provided below and return it to me.  If you do not accept this offer by Thursday, June 24, 2021, the offer will be deemed withdrawn.  
Sincerely,

By: /s/ Amy Sheehan_______________________
                                       Amy R. Sheehan
                                       Senior Vice President & Chief HR Officer

The foregoing letter correctly sets forth the terms of my at-will employment with IVERIC bio, Inc., which I hereby accept.  Nothing contained in this letter abrogates the at-will status of my proposed employment.  I am not relying on any representations other than those set forth above.
/s/ Chris Simms_________________        ________________________
Christopher Simms                    Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]